glp-1 para que sirve La revolución metabólica de los agonistas del GLP-1: éxitos y riesgos GLP-1 y GIP: Las hormonas

Individual results vary on these medications, and they should never replace any blood pressure medications youve been prescribed

doi:10.3748/wjg.v31.i37.111435

Heterogeneity in study design, patient populations and specific GLP1RAs examined likely contributes to these inconsistencies

The phase 3 SURMOUNT programme assessed the safety and efficacy of tirzepatide as obesity treatment and the medication has now been approved (November 2023) for chronic weight management by the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) [46, 47]

FDA regulatory status - compounded GLP-1s: FDA proposed April 30, 2026 to exclude semaglutide and tirzepatide from 503B Bulks List

Data were extracted using a standardized form, and the process was conducted independently by both reviewers to ensure accuracy and minimize bias